{
  "nctrialId": "HC-1766",
  "title": "A Randomized Open-Label, Placebo-Controlled  Study of CAN-456 (receptor antagonist) in Patients With Irritable Bowel Syndrome",
  "officialTitle": "A Randomized Open-Label, Placebo-Controlled  Study of CAN-456 (receptor antagonist) in Patients With Irritable Bowel Syndrome",
  "sponsor": "University of Alberta",
  "indication": "Irritable Bowel Syndrome",
  "phase": "Phase 1/Phase 2",
  "fileName": "HC-1766.json",
  "fileSize": 171534,
  "date": "2023-12-19",
  "completionDate": "2027-02-07",
  "drugName": "CAN-456 (receptor antagonist)",
  "source": "Health Canada Clinical Trials Database",
  "studyType": "Interventional",
  "status": "Active, not recruiting",
  "description": "This is a randomized open-label, placebo-controlled  study designed to evaluate the efficacy and safety of CAN-456 (receptor antagonist) in patients with Irritable Bowel Syndrome. The study will enroll approximately 414 patients.",
  "eligibilityCriteria": "\nInclusion Criteria:\n- Adults aged 19-58 years\n- Confirmed diagnosis of Irritable Bowel Syndrome\n- ECOG performance status 0-1\n- Adequate organ function\n- Willing and able to provide informed consent\n\nExclusion Criteria:\n- Known hypersensitivity to study drug or excipients\n- Pregnant or breastfeeding women\n- Participation in another interventional study within 30 days\n- Significant cardiovascular disease within past 6 months\n- Active or chronic infection requiring systemic treatment",
  "csr_id": "HC-1766"
}